Anti-VEGF and anti-VEGFR treatments have also largely been shown to be beneficial in treating obesity in pre-clinical obesity models (Cao, 2014; Leong-Poi, 2014). This evidence concerns the gene KDR and obesity due to melanocortin 4 receptor deficiency.